Your current position:HOME > Products & Services > Tumor Gene Detection > Lung Cancer
Products & Services
Summary of Lung Cancer
Lung cancer is a common malignant tumor on lungs; it severely endangers human health and life. According to the latest statistics, in 2015, there were about 733,000 new cases of lung cancer in our country, ranking first in incidence of malignant tumors, the incidence for males is about twice that of females; meanwhile, in 2015, there were about 610,000 death cases of lung cancer, ranking first in death rate of malignant tumors. 
Histologically, lung cancer can be divided into non-small cell lung cancer and small cell lung cancer, among which, the former accounts for above 85%. The non-small cell lung cancer can be divided into lung adenocarcinoma, squamous carcinoma and large cell carcinoma, among which, the lung adenocarcinoma has the highest incidence, about two thirds of that of primary lung cancer. According to the type and stage, the treatment can be divided into four types: surgery, chemotherapy, radiotherapy and targeted therapy.
Scientific studies have verified that a cancer is caused by the genetic mutation of human body; genetic mutation can lead to infinite proliferation of cells due to losing of normal control ability, eventually resulting in occurrence of cancer. While the targeted drugs can kill the tumor cells carrying specific gene variations, with apparent curative effects, therefore, it is regarded as a first choice for advanced cancer patients in multiple cancer types. Presently, Iressa, Tarceva, Conmana, Xalkori, Afatinib, Ceritinib, Alectinib and Tagrisso have been approved by FDA/CFDA. However, the gene variations carried by different patients are different, which makes patients with different sensitivity, toxic and adverse effects for same antineoplastic drugs.

In American cancer diagnosis and treatment guideline, genes concerning targeted drugs of non-small cell lung cancer are recommended, besides the conventionally commended and detected EGFR and ALK gene variations, BRAF, MET, RET, ROS1 and HER2 are also listed into recommended detection scope. Presently, the commercial targeted drugs have been developed for these gene variations.
The precision diagnosis is a prerequisite for accurate medication. The idea of molecular genotype makes the doctors formulate best therapeutic regimen according to biomarkers carried by lung cancer patients and corresponding clinical status, to greatly find out potentially available targeted drugs and enhance treatment efficiency of antineoplastic drugs.
The occurrence of tumors is often accompanied by multiple gene variations and heterogeneity. As more and more driver genes of lung cancer targets have been found, the traditional single detection technology can’t meet the current detection needs. The second generation sequencing technology can realize parallel detection on multiple genes, saving samples compared to traditional detection methods and reaching higher technology sensitivity, to restore tumor mutation in a more real manner.
Lung cure ™

Individualized medication gene detection of lung cancer

Burning Rock Lung cure™, aiming at lung cancer patients, by adopting the advanced second-generation sequencing technology, can detect the targets of drug-inhibited 8 genes for one time. For the drug-inhibited target genes detected by Burning Rock Lung cure™, there are definite recommended drug in NCCN guideline, which can provide references for clinical treatment decision.

Detection contents of Lung cure ™


Applicable Populations

Lung cure ™ is suitable for the genetic detecting of the first-line treatment for lung cancer individualized medication, compared with the traditional technology, Lung cureTM has increased more than 30% of detection rate of medication genovariation.
Lung core™

Individualized medication gene detection  for lung cancer

Burning Rock Lung core™, targeted at patients with lung cancer, by applying the advanced second generation sequencing technology, comprehensively detects the drug-inhibited target spot suggested in non-small cell lung cancer NCCN guideline, and drug-inhibited target spot in researched in the phase Ⅱ/Ⅲ clinical trial, which can provide reference information for selection of individualized treatment for lung cancer clinically.

Genes covered in Lung core™

Targeted Drugs covered in Lung core™

  • More comprehensive individualized medication choice for lung cancer:

Lung core™ Comprehensively detects the drug-inhibited target gene suggested in non-small cell lung cancer NCCN guideline, drug-inhibited target spot researched in the phase Ⅱ/Ⅲ clinical trial of lung cancer, as well as approved drug-inhibited target spot in all kinds of cancers, and provides the most comprehensive individualized medication genetic detecting of lung cancer;
  • More accurate gene mutation detection related to lung cancer:

The gene detection Panel based on the second generation sequencing technology optimized by Burning Rock Dx, can detect 4 types of variation types at one time (mutation, indel, fusion, amplification, etc.), at the same time, applies high sequencing to deeply cover trace genovariation, so as to provide full view of the precise genovariation although samples are limited. On the one hand, the parallel detecting with the polygenic high sensitivity  improves the detection rate of drug-inhibited genovariation, which is able to miss opportunity of dedication; on the other hand, the complete coverage of exons can detect the hot spot and rare even unknown genovariation at the same time in one detection, detect related drug-resistant mutation while discovering drug sensitivity mutation(such as KRAS and ALK point mutation),  having an accurate reflection of the sensitivity and drug resistance information of the patients after the usage of medication.
  • More professional detection report interpretation:

Buring Rock Dx, having the patented automated analysis system, is also the domestic third party detecting company only owning the professional medical department. The improved software and hardware resources ensures the accuracy of every detection report, which provides accurate and comprehensive basis of designing more reasonable individualized treatment scheme for doctors.

Applicable Populations


Sample Requirements

Operation organization and biopsy samples, fresh tissues or paraffin embedding samples are available.

Service Cycle

After sample inspection, detailed detection report will be issued in 10 natural days.

Service Procedure

Cases Sharing